BERKELEY HEIGHTS, N.J., Oct. 15, 2012 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), will host a conference call today to discuss updated data from an ongoing, multicenter, Phase 2 randomized trial of oral sapacitabine capsules, the Company's lead product candidate, in older patients with intermediate-2 or high-risk myelodysplastic syndromes (MDS) after treatment failure of front-line hypomethylating agents, such as azacitidine (Vidaza®) and/or decitabine (Dacogen®).
The data were recently discussed at two separate sessions at The Eighth Annual Hematologic Malignancies 2012 Conference being held on October 10-14, 2012, in Houston, Texas. Median overall survival to date for all 63 patients in the Phase 2 study is 252 days or approximately 8 months. Median overall survival for 41 out of 63 patients with 10% or more blasts in their bone marrow is 274 days or approximately 9 months.
In addition to Cyclacel senior management, Guillermo Garcia-Manero, M.D., Chief of the Section of Myelodysplastic Syndromes and Professor, Department of Leukemia and Hagop Kantarjian, M.D., Chairman & Professor, Department of Leukemia, both with The University of Texas MD Anderson Cancer Center, will review and discuss the findings from the Phase 2 trial. The call is scheduled for Monday, October 15, 2012, starting at 3:30 p.m. (ET) and can be accessed by dialing (877) 493-9121 (domestic) or (973) 582-2750 (international) and providing the pass code 44048598. A replay of the call will be available approximately two hours after completion of the call and will be archived for three weeks.Study Results Updated median survival for all three arms is 252 days (approximately 8 months). The median survival for each arm is 291 days (approximately 10 months) for Arm G, 274 days (approximately 9 months) for Arm H, and 227 days (approximately 8 months) for Arm I. Twenty-seven percent of all patients received 6 or more cycles. Twenty-two percent of patients are still alive and longer follow-up is needed to assess 1-year survival and overall survival of each arm.